Value
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.7 |
| P/S | 9.9 |
| EV/EBITDA | 10.0 |
| Fwd P/E | 8.2 |
| PEG | 3.4 |
| Analyst target | 3.0 |
- ▸Forward P/E: 14.4x
- ▸PEG: 3.49
NVO · Why this verdict
Why Novo Nordisk A/S (NVO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Novo Nordisk is a large-cap pharmaceutical company with exceptional 71% return on equity, 37% net margins, and 24% revenue growth, but a confirmed long-term downtrend, elevated put/call ratio of 4.95, and consecutive earnings misses create near-term caution.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Novo Nordisk delivers an ROE of 71%, net margins of 37%, and revenue growth of 24% year-over-year, which ranks as best-in-class compared to pharmaceutical peers on both margin and returns metrics. Quality breakdown | Net margin stays above 30% and ROE remains above 50% for the next 4 reporting quarters, confirming the quality profile is durable. | →Stable |
| CounterA Rule of 40 score of only 20 is a failing grade for a high-growth pharma, and the free cash flow quality flag shows that reported earnings exceed actual cash generation, which can distort margin analysis. | ||
Novo Nordisk missed EPS estimates in 2 of the last 4 quarters, with the most recent quarter showing a 4.75% miss, suggesting that revenue and margin growth is beginning to decelerate below what the market has modeled. Earnings | EPS surprise turns positive in at least 3 of the next 4 quarters as expectations are reset to more achievable levels. | →Stable |
| CounterTwo misses in four quarters with near-zero average surprise of 0.72% indicates that execution is very close to expectations, and the miss streak may simply reflect conservative analyst modeling rather than a fundamental deceleration. | ||
The 200-day moving average slope is declining at negative 3.0% per month, confirmed as a structural downtrend, which creates a technical headwind that makes buying into this quality franchise more risky than the fundamentals alone would suggest. Momentum breakdown | The 200-day moving average slope turns positive within 6 months, signaling that the long-term downtrend is reversing. | →Stable |
| CounterFor a fundamentally strong business with 24% revenue growth, a price downtrend may represent a buying opportunity rather than a deteriorating thesis, as earnings fundamentals eventually reassert themselves over technical trends. | ||
The put/call ratio of 4.95 is extremely elevated, indicating that options market participants are buying protection against a significant further decline, which historically precedes continued downward pressure or at minimum elevated volatility. Options | The put/call ratio falls below 2.0 within 3 months as the negative sentiment overhang unwinds. | →Stable |
| CounterAn elevated put/call ratio can also reflect large institutions hedging long positions rather than building net short exposure, making it an ambiguous signal rather than a pure bearish indicator. | ||
Novo Nordisk delivers an ROE of 71%, net margins of 37%, and revenue growth of 24% year-over-year, which ranks as best-in-class compared to pharmaceutical peers on both margin and returns metrics.
→StableQuality breakdown
- Expectation
- Net margin stays above 30% and ROE remains above 50% for the next 4 reporting quarters, confirming the quality profile is durable.
CounterA Rule of 40 score of only 20 is a failing grade for a high-growth pharma, and the free cash flow quality flag shows that reported earnings exceed actual cash generation, which can distort margin analysis.
Novo Nordisk missed EPS estimates in 2 of the last 4 quarters, with the most recent quarter showing a 4.75% miss, suggesting that revenue and margin growth is beginning to decelerate below what the market has modeled.
→StableEarnings
- Expectation
- EPS surprise turns positive in at least 3 of the next 4 quarters as expectations are reset to more achievable levels.
CounterTwo misses in four quarters with near-zero average surprise of 0.72% indicates that execution is very close to expectations, and the miss streak may simply reflect conservative analyst modeling rather than a fundamental deceleration.
The 200-day moving average slope is declining at negative 3.0% per month, confirmed as a structural downtrend, which creates a technical headwind that makes buying into this quality franchise more risky than the fundamentals alone would suggest.
→StableMomentum breakdown
- Expectation
- The 200-day moving average slope turns positive within 6 months, signaling that the long-term downtrend is reversing.
CounterFor a fundamentally strong business with 24% revenue growth, a price downtrend may represent a buying opportunity rather than a deteriorating thesis, as earnings fundamentals eventually reassert themselves over technical trends.
The put/call ratio of 4.95 is extremely elevated, indicating that options market participants are buying protection against a significant further decline, which historically precedes continued downward pressure or at minimum elevated volatility.
→StableOptions
- Expectation
- The put/call ratio falls below 2.0 within 3 months as the negative sentiment overhang unwinds.
CounterAn elevated put/call ratio can also reflect large institutions hedging long positions rather than building net short exposure, making it an ambiguous signal rather than a pure bearish indicator.
Per-dimension breakdown
Quality
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 3.2 |
| FCF quality | 0.0 |
| Moat | 8.2 |
| Rule of 40 | 3.0 |
| Piotroski F | 7.8 |
- ▸Excellent ROE: 71%
- ▸Strong margins: 37%
- ▸Earnings quality RED FLAG: -10% FCF/NI
- ▸Wide economic moat
Growth
9.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 8.5 |
| EPS growth | 10.0 |
- ▸Strong growth: 24% YoY
Momentum
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 8.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 7.1 |
| Price target | 4.6 |
Insider
5.0/10data confidence 50%Peer rank
7.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.8 |
| quality rank | 8.7 |
| growth rank | 8.8 |
- ▸Attractive P/E vs peers
- ▸Best-in-class margins
Technical
0.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.4 |
| 52w position | 2.2 |
Risk (lower is worse)
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.6 |
| days to cover | 9.5 |
| volatility | 5.0 |
| put call | 7.8 |
| implied vol | 4.2 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 6.7 |
| news risk | 3.0 |
- ▸Above max pain $25
Catalyst
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 2.9 |
| dividend safety | 6.5 |
| news activity | 8.0 |
- ▸Earnings concerns: 2B/2M
- ▸Dividend: 380.0%
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more. | News modifier -1 (HOLD_IF_HOLDING → SELL_IF_HOLDING).
Engine technical detail
verdict_path:
L4:PATH_F_HOLD|L3:NEWS_MOD=-1Passed (7)
- MOMENTUM:6.6>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:41d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.1=NEGATIVE
Warning (1)
- DEATH_CROSS:momentum=6.6>=5.0 recovering
Reward-to-Risk
-1.05
Upside
-15.2%
Downside
14.5%
Sizing output
AVOID
SetupMOMENTUM_CONT — Trend continuation, RSI 69, MACD bullish
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:6.6>=5.5. Top dim: Growth at 9.2; weakest: Technical at 0.9. No conviction either direction.
The strongest dimensions are Growth at 9.2, Peer rank at 7.8, and Quality at 7.2; the weakest are Technical at 0.9, Insider at 5.0, and Catalyst at 5.1. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -1.05 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Novo Nordisk delivers an ROE of 71%, net margins of 37%, and revenue growth of 24% year-over-year, which ranks as best-in-class compared to pharmaceutical peers on both margin and returns metrics.
Trip ifNet margin falls below 25% for 2 consecutive quarters.
- P2The 200-day moving average slope is declining at negative 3.0% per month, confirmed as a structural downtrend, which creates a technical headwind that makes buying into this quality franchise more risky than the fundamentals alone would suggest.
Trip ifThe 200-day moving average slope remains negative at more than negative 2% per month for 6 consecutive months.
- P3The put/call ratio of 4.95 is extremely elevated, indicating that options market participants are buying protection against a significant further decline, which historically precedes continued downward pressure or at minimum elevated volatility.
Trip ifPut/call ratio rises above 6.0 or remains above 3.0 for more than 60 consecutive days.
- P4Novo Nordisk missed EPS estimates in 2 of the last 4 quarters, with the most recent quarter showing a 4.75% miss, suggesting that revenue and margin growth is beginning to decelerate below what the market has modeled.
Trip ifEPS surprise falls below negative 5% in at least 3 of the next 4 quarters.